ZEB1-AS1 mediates bone metastasis through targeting miR-320b/BMPR1A axis in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
• ZEB1-AS1 has emerged as a potential oncogenic lncRNA in various cancers.

Purpose of the Study:

• To investigate the role of lncRNA ZEB1-AS1 in lung cancer.
• To elucidate the regulatory mechanism of ZEB1-AS1 in lung cancer progression and metastasis.
• To explore the potential of ZEB1-AS1 as a therapeutic target.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to assess ZEB1-AS1 and miR-320b expression.
• Cell-based assays (CCK-8, colony-forming, Transwell) to evaluate cell viability, proliferation, migration, and invasion.
• Western blot to quantify epithelial-mesenchymal transition (EMT) markers.
• In vivo mouse models to assess tumor growth and bone metastasis, followed by H&E staining.

Main Results:

• ZEB1-AS1 expression was significantly upregulated in lung cancer tissues and cells.
• Knockdown of ZEB1-AS1 suppressed lung cancer cell viability, proliferation, migration, invasion, and EMT.
• ZEB1-AS1 was found to target miR-320b, which in turn targets BMPR1A, forming the ZEB1-AS1/miR-320b/BMPR1A axis.
• In vivo studies confirmed ZEB1-AS1 promotes lung cancer bone metastasis via this axis.

Conclusions:

• ZEB1-AS1 plays a crucial role in promoting lung cancer cell proliferation, migration, invasion, and EMT.
• The ZEB1-AS1/miR-320b/BMPR1A axis is a key regulatory pathway in lung cancer progression.
• ZEB1-AS1 mediates lung cancer bone metastasis, highlighting its potential as a therapeutic target.